1. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 2013;19:1438-49.
2. Ocana OH, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012;22:709-24.
3. Huang Q, Wang Y, Chen X, Wang Y, Li Z, et al. Nanotechnology-Based Strategies for Early Cancer Diagnosis Using Circulating Tumor Cells as a Liquid Biopsy. Nanotheranostics 2018;2:21-41.
4. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013;31:539-44.
6. Huang Q, Chen B, He R, He Z, Cai B, et al. Capture and release of cancer cells based on sacrificeable transparent MnO2 nanospheres thin film. Adv Healthc Mater 2014;3:1420-5.
7. Huang Q, Cai B, Chen B, Rao L, He Z, et al. Efficient Purification and Release of Circulating Tumor Cells by Synergistic Effect of Biomarker and SiO2 @Gel-Microbead-Based Size Difference Amplification. Adv Healthc Mater 2016;5:1554-9.
8. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9.
9. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006;12:4218-24.
10. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213-21.
11. Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A 2009;106:3970-5.
12. Saliba AE, Saias L, Psychari E, Minc N, Simon D, et al. Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. Proc Natl Acad Sci U S A 2010;107:14524-9.
13. Earhart CM, Hughes CE, Gaster RS, Ooi CC, Wilson RJ, et al. Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. Lab Chip 2014;14:78-88.
14. Fina E, Callari M, Reduzzi C, D’Aiuto F, Mariani G, et al. Gene expression profiling of circulating tumor cells in breast cancer. Clin Chem 2015;61:278-89.
15. Mayo C, Ortega FG, Gimenez-Capitan A, Molina-Vila MA, Serrano MJ, et al. CK-coated magnetic-based beads as a tool to isolate circulating tumor cells (CTCs) in human tumors. Transl Lung Cancer Res 2013;2:65-71.
16. Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013;59:110-8.
18. Neves M, Azevedo R, Lima L, Oliveira MI, Peixoto A, et al. Exploring sialyl-Tn expression in microfluidic-isolated circulating tumour cells: A novel biomarker and an analytical tool for precision oncology applications. N Biotechnol 2019;49:77-87.
19. Yokobori T, Iinuma H, Shimamura T, Imoto S, Sugimachi K, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res 2013;73:2059-69.
20. Takakura M, Matsumoto T, Nakamura M, Mizumoto Y, Myojyo S, et al. Detection of circulating tumor cells in cervical cancer using a conditionally replicative adenovirus targeting telomerase-positive cells. Cancer Sci 2018;109:231-40.
21. Dorsey JF, Kao GD, MacArthur KM, Ju M, Steinmetz D, et al. Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: Pilot study results. Cancer 2015;121:139-49.
22. Frick MA, Kao GD, Aguarin L, Chinniah C, Swisher-McClure S, et al. Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study. Int J Radiat Oncol Biol Phys 2018;102:536-42.
23. Agerbæk MO, Bang-Christensen SR, Yang MH, Clausen TM, Pereira MA, et al. The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner. Nat Commun 2018;9:3279.
24. Ding C, Zhou X, Xu C, Chen J, Ju S, et al. Circulating tumor cell levels and carcinoembryonic antigen: An improved diagnostic method for lung adenocarcinoma. Thorac Cancer 2018;9:1413-20.
25. Neil JR, Johnson KM, Nemenoff RA, Schiemann WP. Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis 2008;29:2227-35.
26. Cai J, Huang L, Huang J, Kang L, Lin H, et al. Associations between the cyclooxygenase-2 expression in circulating tumor cells and the clinicopathological features of patients with colorectal cancer. J Cell Biochem 2018:1-7.
27. Huang Q, Wang FB, Yuan CH, He Z, Rao L, et al. Gelatin Nanoparticle-Coated Silicon Beads for Density-Selective Capture and Release of Heterogeneous Circulating Tumor Cells with High Purity. Theranostics 2018;8:1624-35.
28. He Y, Shi J, Shi G, Xu X, Liu Q, et al. Using the New CellCollector to Capture Circulating Tumor Cells from Blood in Different Groups of Pulmonary Disease: A Cohort Study. Sci Rep 2017;7:9542.
29. Gallerani G, Cocchi C, Bocchini M, Piccinini F, Fabbri F. Characterization of tumor cells using a medical wire for capturing circulating tumor cells: A 3D approach based on immunofluorescence and DNA FISH. J Vis Exp 2017:e56936.
30. Markou A, Lazaridou M, Paraskevopoulos P, Chen S, Swierczewska M, et al. Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients. Clin Chem 2018;64:297-306.
31. Ramirez JM, Fehm T, Orsini M, Cayrefourcq L, Maudelonde T, et al. Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients. Clin Chem 2014;60:214-21.
32. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235-9.
33. Sequist LV, Nagrath S, Toner M, Haber DA, Lynch TJ. The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol 2009;4:281-3.
34. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 2013;5:179-47.
35. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 2010;107:18392-7.
36. Wang S, Liu K, Liu J, Yu ZT, Xu X, et al. Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angew Chem Int Ed Engl 2011;50:3084-8.
37. Sekine J, Luo SC, Wang S, Zhu B, Tseng HR, et al. Functionalized conducting polymer nanodots for enhanced cell capturing: the synergistic effect of capture agents and nanostructures. Adv Mater 2011;23:4788-92.
38. Zhang N, Deng Y, Tai Q, Cheng B, Zhao L, et al. Electrospun TiO2 nanofiber-based cell capture assay for detecting circulating tumor cells from colorectal and gastric cancer patients. Adv Mater 2012;24:2756-60.
39. Shen Q, Xu L, Zhao L, Wu D, Fan Y, et al. Specific capture and release of circulating tumor cells using aptamer-modified nanosubstrates. Adv Mater 2013;25:2368-73.
40. Hou S, Zhao L, Shen Q, Yu J, Ng C, et al. Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew Chem Int Ed Engl 2013;52:3379-83.
41. Hou S, Zhao H, Zhao L, Shen Q, Wei KS, et al. Capture and stimulated release of circulating tumor cells on polymer-grafted silicon nanostructures. Adv Mater 2013;25:1547-51.
42. Dong Z, Yu D, Liu Q, Ding Z, Lyons VJ, et al. Enhanced capture and release of circulating tumor cells using hollow glass microspheres with a nanostructured surface. Nanoscale 2018;10:16795-804.
43. Wu X, Xiao T, Luo Z, He R, Cao Y, et al. A micro-/nano-chip and quantum dots-based 3D cytosensor for quantitative analysis of circulating tumor cells. J Nanobiotechnology 2018;16:65.
44. Sheng W, Chen T, Tan W, Fan ZH. Multivalent DNA nanospheres for enhanced capture of cancer cells in microfluidic devices. ACS Nano 2013;7:7067-76.
45. Poudineh M, Aldridge PM, Ahmed S, Green BJ, Kermanshah L, et al. Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking. Nat Nanotechnol 2017;12:274-81.
46. Mohamadi RM, Besant JD, Mepham A, Green B, Mahmoudian L, et al. Nanoparticle-mediated binning and profiling of heterogeneous circulating tumor cell subpopulations. Angew Chem Int Ed Engl 2015;54:139-43.
47. Bai M, Zou B, Wang Z, Li P, Wang H, et al. Comparison of two detection systems for circulating tumor cells among patients with renal cell carcinoma. Int Urol Nephrol 2018;50:1801-9.
48. Chen F, Wang S, Fang Y, Zheng L, Zhi X, et al. Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application. Oncotarget 2017;8:3029-41.
49. Obermayr E, Maritschnegg E, Agreiter C, Pecha N, Speiser P, et al. Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells. Oncotarget 2018;9:812-23.
50. Lee Y, Guan G, Bhagat AA. ClearCell(R) FX, a label-free microfluidics technology for enrichment of viable circulating tumor cells. Cytometry A 2018;93:1251-4.
51. Yanagita M, Luke JJ, Hodi FS, Janne PA, Paweletz CP. Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization. Melanoma Res 2018;28:89-95.
52. Qin L, Zhou W, Zhang S, Cheng B, Wang S, et al. Highly efficient isolation of circulating tumor cells using a simple wedge-shaped microfluicdic device. IEEE Trans Biomed Eng 2018; doi: 10.1109/TBME.2018.2875361.
53. Liu F, Wang S, Lu Z, Sun Y, Yang C, et al. A simple pyramid-shaped microchamber towards highly efficient isolation of circulating tumor cells from breast cancer patients. Biomed Microdevices 2018;20:83.
54. Sollier-Christen E, Renier C, Kaplan T, Kfir E, Crouse SC. VTX-1 Liquid Biopsy System for Fully-Automated and Label-Free Isolation of Circulating Tumor Cells with Automated Enumeration by BioView Platform. Cytometry A 2018;93:1240-5.
55. Wardlaw SC, Levine RA. Quantitative buffy coat analysis. A new laboratory tool functioning as a screening complete blood cell count. JAMA 1983;249:617-20.
56. Kaldjian EP, Ramirez AB, Sun Y, Campton DE, Werbin JL, et al. The RareCyte(R) platform for next-generation analysis of circulating tumor cells. Cytometry A 2018;93:1220-5.10.
57. Nguyen NV, Jen CP. Impedance detection integrated with dielectrophoresis enrichment platform for lung circulating tumor cells in a microfluidic channel. Biosens Bioelectron 2018;121:10-8.
58. Chalopin A, Tellez-Gabriel M, Brown HK, Vallette F, Heymann MF, et al. Isolation of circulating tumor cells in a preclinical model of osteosarcoma: effect of chemotherapy. J Bone Oncol 2018;12:83-90.
59. Bahnassy AA, Saber MM, Mahmoud MG, Abdellateif MS, Abd El-Mooti Samra M, et al. The role of circulating tumor cells in metastatic breast cancer: prognostic and predictive value. Mol Biol Rep 2018;45:2025-35.
60. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77.
61. Alama A, Truini A, Coco S, Genova C, Grossi F. Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. Drug Discov Today 2014;19:1671-6.
62. Ding C, Zhou X, Xu C, Chen J, Ju S, et al. Circulating tumor cell levels and carcinoembryonic antigen: An improved diagnostic method for lung adenocarcinoma. Thorac Cancer 2018;9:1413-20.
63. Zhu Y, Piehowski PD, Zhao R, Chen J, Shen Y, et al. Nanodroplet processing platform for deep and quantitative proteome profiling of 10-100 mammalian cells. Nat Commun 2018;9:882.
64. Zhu Y, Podolak J, Zhao R, Shukla AK, Moore RJ, et al. Proteome Profiling of 1 to 5 Spiked Circulating Tumor Cells Isolated from Whole Blood Using Immunodensity Enrichment, Laser Capture Microdissection, Nanodroplet Sample Processing, and Ultrasensitive nanoLC-MS. Anal Chem 2018;90:11756-9.
65. Dhar M, Lam JN, Walser T, Dubinett SM, Rettig MB, et al. Functional profiling of circulating tumor cells with an integrated vortex capture and single-cell protease activity assay. Proc Natl Acad Sci U S A 2018;115:9986-91.
66. Ortega FG, Lorente JA, Garcia Puche JL, Ruiz MP, Sanchez-Martin RM, et al. miRNA in situ hybridization in circulating tumor cells--MishCTC. Sci Rep 2015;5:9207.
67. Frithiof H, Aaltonen K, Ryden L. A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation. Onco Targets Ther 2016;9:7095-103.
68. Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005;65:4993-7.
69. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 2012;14:R15.
70. Mostert B, Sieuwerts AM, Bolt-de Vries J, Kraan J, Lalmahomed Z, et al. mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients. Mol Oncol 2015;9:920-32.
71. Campton DE, Ramirez AB, Nordberg JJ, Drovetto N, Clein AC, et al. High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. Bmc Cancer 2015;15:360.
72. Kaveh F, Baumbusch LO, Nebdal D, Borresen-Dale AL, Lingjaerde OC, et al. A systematic comparison of copy number alterations in four types of female cancer. BMC Cancer 2016;16:913.
74. Bertucci F, Finetti P, Guille A, Adelaide J, Garnier S, et al. Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget 2016;7:27208-19.
75. Ting DT, Wittner BS, Ligorio M, Vincent Jordan N, Shah AM, et al. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep 2014;8:1905-18.
76. Ni X, Zhuo M, Su Z, Duan J, Gao Y, et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A 2013;110:21083-8.
77. Trapp E, Janni W, Schindlbeck C, Juckstock J, Andergassen U, et al. Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. J Natl Cancer Inst 2019;111:380-7.
78. Yang C, Shi D, Wang S, Wei C, Zhang C, et al. Prognostic value of pre- and post-operative circulating tumor cells detection in colorectal cancer patients treated with curative resection: a prospective cohort study based on ISET device. Cancer Manag Res 2018;10:4135-44.
79. Nicola N, Antonio R, Alessandro M, Simona S, Simona B, et al. Prognostic value of circulating tumor cells’ reduction in patients with extensive small-cell lung cancer. Lung Cancer 2014;85:314-9.
80. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014;32:3483-9.
81. Wen YF, Cheng TT, Chen XL, Huang WJ, Peng HH, et al. Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy. PLoS One 2018;13:e0204334.
82. Wu ZX, Liu Z, Jiang HL, Pan HM, Han WD. Circulating tumor cells predict survival benefit from chemotherapy in patients with lung cancer. Oncotarget 2016;7:67586-96.
83. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. J Natl Cancer Inst 2018;110:560-7.
84. Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol 2015;67:4-17.
85. Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, et al. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A 2018;115:2467-72.
86. Namatame N, Tamaki N, Yoshizawa Y, Okamura M, Nishimura Y, et al. Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines. Oncotarget 2018;9:35141-61.
87. Grunwald V, Keilholz U, Boehm A, Guntinas-Lichius O, Hennemann B, et al. TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). Ann Oncol 2015;26:561-7.
88. Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 2015;9:1773-82.
89. Kim YR, Yoo JK, Jeong CW, Choi JW. Selective killing of circulating tumor cells prevents metastasis and extends survival. J Hematol Oncol 2018;11:114.
90. Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med 2018;10.
91. Nakamura K, Sawada K, Yoshimura A, Kinose Y, Nakatsuka E, et al. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer 2016;15:48.
92. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015;523:177-82.
93. Halvorsen AR, Sandhu V, Sprauten M, Flote VG, Kure EH, et al. Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. Acta Oncol 2018;57:1225-31.
94. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-50.
95. Ilie M, Szafer-Glusman E, Hofman V, Chamorey E, Lalvee S, et al. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ann Oncol 2018;29:193-9.
96. Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M, et al. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. Ann Oncol 2017;28:1923-33.
97. Boffa DJ, Graf RP, Salazar MC, Hoag J, Lu D, et al. Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. Cancer Epidemiol Biomarkers Prev 2017;26:1139-45.
98. Kulasinghe A, Perry C, Kenny L, Warkiani ME, Nelson C, et al. PD-L1 expressing circulating tumour cells in head and neck cancers. BMC Cancer 2017;17:333.
99. Hall CS, Karhade M, Laubacher BA, Kuerer HM, Krishnamurthy S, et al. Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst 2015;107.
100. Bidard F-C, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. The Lancet Oncology 2014;15:406-14.
101. Barbazan J, Muinelo-Romay L, Vieito M, Candamio S, Diaz-Lopez A, et al. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer. Int J Cancer 2014;135:2633-43.
102. Romiti A, Raffa S, Di Rocco R, Roberto M, Milano A, et al. Circulating tumor cells count predicts survival in colorectal cancer patients. J Gastrointestin Liver Dis 2014;23:279-84.
103. Zhou J, Dong F, Cui F, Xu R, Tang X. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2017;79:825-33.
104. Muinelo-Romay L, Vieito M, Abalo A, Nocelo MA, Baron F, et al. Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment. Cancers (Basel) 2014;6:153-65.
105. Messaritakis I, Politaki E, Kotsakis A, Dermitzaki EK, Koinis F, et al. Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer. PLoS One 2017;12:e0181211.
106. Messaritakis I, Politaki E, Plataki M, Karavassilis V, Kentepozidis N, et al. Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib. Lung Cancer 2017;104:16-23.
107. Li Y, Gong J, Zhang Q, Lu Z, Gao J, et al. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. Br J Cancer 2016;114:138-45.
108. Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, et al. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. Cancer 2016;122:1434-43.
109. Pernot S, Badoual C, Terme M, Castan F, Cazes A, et al. Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. Eur J Cancer 2017;79:15-22.
110. Kubisch I, de Albuquerque A, Schuppan D, Kaul S, Schaich M, et al. Prognostic Role of a Multimarker Analysis of Circulating Tumor Cells in Advanced Gastric and Gastroesophageal Adenocarcinomas. Oncology 2015;89:294-303.
111. Brungs D, Lynch D, Luk AW, Minaei E, Ranson M, et al. Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer. World J Gastroenterol 2018;24:810-8.